Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes: Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate, see structure) injection treatment was used along with insulin...
Ref : http://amln.client.shareholder.com/releasedetail.cfm?ReleaseID=681698
